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ABSTRACT
The role of estrogen in breast cancer has been recognized for decades. The
selective estrogen receptor modulator tamoxifen was the first targeted therapy for the
treatment of breast cancer. It was also the first drug approved by the FDA for the
reduction of breast cancer risk. While tamoxifen has extended the lives of countless
patients with breast cancer, resistance to tamoxifen remains a significant clinical
problem. Work over the last two decades has greatly enhanced our understanding of the
molecular mechanisms by which breast cancer cells may become resistant to tamoxifen
treatment. Here I review our current understanding of the tamoxifen’s mechanism of
altering estrogen signaling along with the current experimental and clinical work
investigating the mechanisms by which breast cancer cells develop resistance.
Elucidation of the molecular mechanisms underlying tamoxifen resistance will allow
improvement of treatment by potentially enhancing the effects of tamoxifen while
reducing the incidence of resistance.
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CHAPTER 1. INTRODUCTION
The American Cancer Society estimates that in 2009, 192,370 new cases of
invasive breast cancer and 62,280 additional cases of in situ breast cancer were diagnosed
among women, as well as approximately 40,170 deaths resulting from breast cancer [1].
Treatments for breast cancer include surgery, radiation therapy, and systemic therapy.
Surgery is aimed at removing the cancer from the breast and assessing the stage of
disease, where as radiation therapy may be used to destroy the cancer cells remaining
after surgery. Systemic therapy may be neoadjuvant, often used to reduce the size of the
tumor before surgery, or adjuvant to kill remaining undetected cancer cells. Systemic
therapy includes biologic therapy, chemotherapy, and hormone therapy. Endocrine
therapy is primarily aimed at interfering with estrogen signaling because of the important
role estrogen plays in many breast cancers. Tamoxifen was the first targeted therapy for
breast cancer as well as the first preventative, however resistance remains a significant
issue. A clearer understanding of the molecular mechanisms by which resistance
develops may prevent its occurrence and optimize treatment of patients with breast
cancer.
1.1. Endocrine Therapy for Breast Cancer
The relationship between hormone therapy and breast cancer was first
acknowledged over a century ago when surgeon Sir George Beatson preformed an
oophorectomy on a patient with advanced breast cancer and observed a dramatic response
[2]. He had no knowledge of the estrogen receptor, but simply noted that removing the
ovaries, the major source of estrogen, could benefit women at the inoperable stage of
disease. The estrogen receptor (ER) was reported in 1973 [3] and the association between
the risk of breast cancer and elevated estrogen has been consistently found in many
subsequent studies [4]. Estrogen stimulates the proliferation of breast epithelial cells, and
has been implicated in the pathogenesis of breast cancer [5].
A meta-analysis of 51 epidemiologic studies enrolling 161,116 women
investigated the relation between risk of breast cancer and use of hormone replacement
therapy and showed that breast cancer risk increased by 2.3% per year of hormone use
compared with an increased risk of 2.8% per year of natural delay in the onset of
menopause [6]. These results imply that hormone use increases the risk of developing
breast cancer and support the role of estrogen in the pathogenesis of breast cancer.
However, before the introduction of pharmacological agents, endocrine therapy for breast
cancer was ablative to remove sources of estrogen by either surgery or radiotherapy [7].
Allen and Doisy first discovered the estrogenic hormones produced in the ovary
[8]. The discovery of estrogen led to questions regarding the mechanism by which
estrogens exert their tissue specificity and if there is a target to block estrogen action.
Previously it was believed that estrogens exert their actions by participating in enzymatic
processes. However, the identification of the estrogen receptor that mediates the diverse
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actions of estrogen without alteration of the hormone itself provided a mechanism to
describe the specificity of action and opened the door to molecular targeting in the
treatment and prevention of breast cancer [9]. Two thirds of breast cancers express the
estrogen receptor, therefore, ER-targeted therapy is widely used in breast cancer to inhibit
signaling through ER and disrupt breast cancer growth [10].
1.2. Estrogen Signaling
Estrogen and estrogen receptors are key regulators of breast epithelial
proliferation, differentiation, and apoptosis [11]. Estrogens are cyclopentanophenanthrene
compounds whose synthesis begins with cholesterol like other sex and adrenal hormones.
The most potent and abundant estrogen in humans is 17-estradiol (E2), but estrone and
estriol are also present at lower levels [12]. Because of their steroid structure, estrogens
can diffuse passively through the cytoplasmic and nuclear membranes in order to interact
with its nuclear receptor. Estrogen plays a broad role in human physiology and has been
implicated in the development or progression of numerous diseases, such as various types
of cancer, osteoporosis, neurodegenerative and cardiovascular diseases, insulin
resistance, lupus erythematosus, endometriosis, and obesity [13]. Two molecular forms of
the estrogen receptor (ER) have been identified, and ER acts as a transcriptional factor
and also interacts with other transcriptional factors and growth factor-dependent kinases.
1.2.1. Estrogen Receptor Subtypes
Estrogen mediates its effects via receptors, which serve as the basis for many
therapeutic interventions. ER is a ligand-activated transcription factor. It belongs to a
superfamily of nuclear receptors that includes other steroid hormone receptors. Jensen
and Jacobsen first demonstrated the existence of this receptor that could bind 17estradiol in the late 1950s, and the first ER was cloned in 1986 [14]. It was believed this
was the single receptor until Kuiper et al. cloned another ER in 1996 from a prostate
cDNA library. Today, the two estrogen receptors are designated ER and ER. The two
proteins are produced by two distinct genes on different chromosomes and display tissue
specific expression, with overlapping distribution: “ER is more expressed in prostate,
bone, ovaries (granulosa cells), lungs, and in various parts of the central and peripheral
nervous system, while ER is predominantly expressed in the pituitary gland, ovaries
(thecal and interstitial cells), uterus, liver, kidneys, adrenals, and the mammary glands”
[15]. It is important to note that both subtypes are expressed in the breast.
ER/ are proteins sharing common regions, designated A/B, C, D, E, and F.
These regions participate in the formation of independent but interacting functional
domains [12]. Figure 1-1 shows the well-defined domain organization of the two
receptors, which show a high degree of similarity at the amino acid level, as well as the
degree of homology in the specific domains. The A/B domain includes the activation
function 1 (AF1), which is the “region responsible for the constitutive and ligand-
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Figure 1-1. Human ERα and ERβ nuclear receptors. A schematic representation of
the structure of human ERα and ERβ is depicted. The numbers outside each box refer to
the amino-acid number, and the percentage of amino-acid homology for each domain is
also shown. The location of each domain on each receptor is designated.
Reprinted with permission. Zilli, M., et al., Molecular mechanisms of endocrine
resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta,
2009. 1795(1): p. 62-81 [15].
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independent transcriptional activity of ER.” The C domain contains the DNA-binding
domain (DBD) and is also important for receptor dimerization. The D domain is a
flexible hinge with a nuclear localization signal, and the E domain is the ligand-binding
domain (LBD) and “harbors a second nuclear localization signal and the activation
function 2 (AF2) responsible for the ligand-dependent activation of ER.” The F domain is
not essential and plays a complex modulatory role on both activities [15].
Soon after the identification of ER, it was demonstrated that several compounds
show receptor selectivity in binding and/or efficacy, and studies have since shown that
ER and ER have distinct biological activities. ERα is the stronger transcriptional
activator of the two ER isoforms, at physiological concentrations of estradiol, coexpression of ERβ results in suppression of both the efficacy and the potency of
hormone-stimulated responses, and therefore the relative expression levels of the two
isoforms are an important determinant of cellular sensitivity to estrogens [16].
Many compounds could no longer be classified simply as “estrogenic” after the
identification of the tissue specific actions of estrogens and the discovery of the role of a
second estrogen receptor. ER ligands do not stimulate uterine growth or induce the
progesterone receptor in the uterus, and ER ligands do not inhibit prostatic growth, and
the term “selective estrogen receptor modulator” (SERM) was introduced to provide a
more generic description of the activity of an ER ligand [14].
1.2.2. Genomic ER Signaling
Estrogen influences the physiology of many target tissues and the long-term
effects of estrogen are mediated predominantly via ERs functioning as DNA-binding
transcription factors. ERs regulate gene expression by both direct (classical) and indirect
(non-classical) binding of an ER to DNA (Figure 1-2). These pathways are referred to as
genomic or “nuclear-initiated steroid signaling (NISS)” pathways [15]. Tissue-specific
responses are a result of the regulation of different genes by ER.
1.2.2.1. Classical Genomic Mechanism
ERs predominantly exist as monomers bound to heat shock proteins in the cell
nucleus. However, estrogen diffuses into the nucleus and binds to ER leading to
conformational changes, phosphorylation and disassociation from the chaperon proteins
and finally dimerization [17]. The ER dimmer may then bind to an estrogen response
element (ERE) upstream of estrogen-dependent genes in the regulatory regions of target
genes. The consensus palindromic ERE was initially described based on the estrogenresponsive sequence from estrogen-responsive genes from the Xenopus laevis A2
promoter: 5’-GGTCAnnnTGACC-3’, but the human genome possesses imperfect
palindromic sequences in their promoter with 3,4, and 5 bp spacers [12].
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Figure 1-2. Estrogen receptor signaling pathways. This illustrates the genomic or
“nuclear-initiated steroid signaling” (NISS) pathways and the non-genomic or
“membrane-initiated steroid signaling” (MISS) pathway and the mechanisms by which
they regulate cell growth.
Reprinted with permission. Zilli, M., et al., Molecular mechanisms of endocrine
resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta,
2009. 1795(1): p. 62-81 [15].
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1.2.2.2. Non-Classical Genomic Mechanism
ERs may also influence gene expression without directly binding to DNA by
interacting with other transcription factors. Such factors include Fos/Jun activating
protein (AP-1) complex, cyclic AMP-response elements (CREs), and Sp1 sites and, this
is the mechanism by which estrogen regulates cyclin D1 and IGFR1 [15].
Via both the classical and non-classical mechanisms, estrogen results in a general
up-regulation of genes regulating cell proliferation and survival and the down-regulation
of genes with anti-proliferative or pro-apoptotic activity and the final result growth
stimulation and apoptosis suppression [18]. Up-regulation is mediated by the two
transactivation domains mentioned above: AF-1 (A/B domain) and AF-2 (E domain).
AF-1 activity is regulated by phosphorylation and is hormone-independent, while AF-2 is
in the ligand-binding domain and therefore hormone-dependent [17].
Estrogen-bound ER can directly or indirectly induce gene transcription only if
AF1 and/or AF2 are activated, and either domain may be dominant depending on the
cellular environment or the specific promoter type, but generally the two act in synergy
[15]. Ligand binding results in a conformational change of ER that uncovers AF-2 and
that exposes a binding surface for further modulation by co-regulatory proteins. The
binding of co-activators enhances the transcriptional activity by forming large complexes
that may recruit histone-acetyltransferase (HAT) leading to chromatin decondensation,
while co-repressors reduce transcription by recruiting histone-deacetylase (HDAC) to the
promoter site resulting in chromatin condensation [15]. The co-regulatory proteins
recruited are affected by the ER conformation which is dependent on the ligand and the
specific ERE sequence to which the ER is bound [19].
Unlike AF-2, AF-1 is ligand independent and activated by phosphorylation at
serine residues subsequent to activation of kinase pathways triggered by growth factor
receptors [15]. Epidermal growth factor receptor (EGFR), insulin-like growth factor-1
receptor (IGFR), and human epidermal growth factor receptor type 2 (HER2) have been
implicated in this mechanism [17]. The mechanism by which estrogen affects AF-1 is not
well understood at this point. It is important to note that in the absence of estrogen,
minimal phosphorylation is responsible for constitutive AF-1 activity and that growth
factor signaling pathways can directly activate ER and subsequent transcription. The
growth factor signaling will be explained further in Section 3.2.2. as a potential
mechanism of resistance to endocrine therapy.
1.2.3. Non-Genomic Mechanism
The membrane-initiated steroid signaling (MISS) pathway is a rapid (in seconds
to minutes) non-genomic mechanism of action, mediated by membrane-associated ER.
This occurs via a population of ERs that exists within caveolar rafts and other domains in
the plasma membrane. ER is associated with caveolin-1 and a variety of proximal
signaling molecules, including G proteins, Src and Ras, and B-Raf. Activation of these
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ERs results in signal cascades from G protein activation. Similarly to many other G
protein coupled receptors, G protein activation by ER leads to the cell-specific
stimulation of phospholipase C, protein kinase C, ERK, or phosphatidylinositol 3-kinase
and nitric-oxide synthase [20]. The activation of these kinases has the ability to activate
growth factors and cytoplasmic kinases, which may in turn phosphorylate ER and its coregulators. This suggests that the non-genomic and genomic activities are complementary
and potentially synergistic [15]. Non-genomic activity is highly dependent on ligand and
is regulated by co-regulatory proteins. The activity is also strongly dependent on the
signal transduction pathways operating within the cell [15].
1.3. Therapeutic Approaches to Target Estrogen Activity
The search for pharmacologic means of antagonizing the biological effects of
estrogen as a therapeutic strategy for women with breast cancer has been ongoing ever
since the link between human breast cancer and estrogen emerged. A strategy to
antagonize estrogen in an attempt to treat/prevent breast cancer may have a severe impact
on a patient’s health by interfering with the significant physiological roles of estrogen in
reproductive tissues, bone, the cardiovascular system and its role in cognitive function
and behavior [21].
“Hormone-receptor (HR) status is an important factor used to determine the
prognosis and treatment of breast cancer” [22]. HR-positive breast cancer may be ERpositive, Progesterone-Receptor–positive or both, and typically responds to treatments
that specifically block or interfere with the function of estrogen or progesterone.
Sensitive tumors are now identified by testing for specific receptors, the degree of
positivity scored, and taken into account when determining a course of therapy. Of 5,993
mammary carcinomas examined by immunohistochemistry by Nadji et al., 75% were
positive for ER and 55% of all tumors reacted positively for PR. All PR-positive tumors
were also positive for ER, and endocrine therapy is indicated as part of adjuvant
treatment for these tumors [23]. There are now several effective options for the treatment
of hormone-receptor positive breast cancer and include selective ER modulators
(SERMs), aromatase inhibitors, and selective ER down-regulators (SERDs).
1.3.1. SERMs
SERMs exert selective agonist or antagonist effects on various estrogen sensitive
tissues. They are a chemically diverse group of compounds that lack the steroid structure
of estrogens, and although the primary structure of SERMs differ strikingly from that of
estrogens (Figure 1-3), they have a tertiary structure that permits their binding to the
ligand-binding domain of the ER [24]. Several of these drugs have been available for
decades, but their tissue-specificity in humans has only recently been acknowledged. The
current clinically available SERMs are Tamoxifen, Toremifene, and Raloxifene, and they
differ slightly in their actions and side effects. The specific mechanism of actions of
SERMs with focus on Tamoxifen will be discussed in greater detail in Section 2.
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Figure 1-3. Chemical structures of 17-Estradiol and the three FDA-approved
SERMs.
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1.3.2. Aromatase Inhibitors
Anti-aromatase agents inhibit the cytochrome P-450 component of the aromatase
enzyme complex, which is responsible for the final step of estrogen biosynthesis. These
drugs are classified into generations, and the third-generation agents are currently
approved for use in the treatment of breast cancer. These are further divided into type I
and type II: Type I inhibitors (exemestane) have a steroidal structure similar to androgens
and inactivate the enzyme irreversibly by blocking the substrate-binding site, while Type
II inhibitors (anastrozole and letrozole) are non-steroidal and their action is reversible
[25].
1.3.3. SERDs
SERDs are also termed ‘pure anti-estrogens,’ and only fulvestrant is being used
clinically. It is showing promising clinical activity in the treatment of advanced breast
cancer. Fulvestrant has a higher affinity for the estrogen receptor (ER) compared to
SERMs, but does not have any of the agonist activities [21]. Fulvestrant is a novel ER
antagonist that binds to the receptor and prevents ER dimerization, leading to rapid
degradation and loss of cellular ER expression [26].
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CHAPTER 2. TAMOXIFEN
2.1. History
For more than 30 years, tamoxifen has been the gold standard for the endocrine
treatment of ER-positive breast cancer, and it is estimated that more than 400,000 women
are alive today as a result of tamoxifen therapy, and millions more have benefited from
palliation and extended disease-free survival [27]. The discovery of non-steroidal antiestrogens by the pharmaceutical industry during the 1960s was initially an exciting
prospect for ‘morning after’ anti-fertility agents. Unfortunately, unlike in the rat, the antiestrogens actually improved fertility by inducing ovulation in subfertile women [28]. The
discovery of the ER in the 1970s and the relationship between estrogen and breast cancer
provided a target in the treatment and prevention of breast cancer. At this point research
into anti-estrogens previously abandoned as anti-fertility agents was revived.
In the laboratory, tamoxifen was demonstrated to prevent the induction of
carcinogen-induced rat mammary tumors and was shown to have efficacy in the
treatment of advanced breast cancer and became the first targeted therapy for breast
cancer when it was approved in 1977 for the treatment of women with metastatic breast
cancer [29]. Over time the widening use of tamoxifen for long-term treatment and the
reduction in the risk of contralateral breast cancer in adjuvant trials led to the evaluation
of its use as a preventative for breast cancer. In 1992, the National Surgical Adjuvant
Breast and Bowel Project (NSABP) implemented a randomized clinical trial to evaluate
tamoxifen’s potential in the prevention of breast cancer in 13,800 high risk women and
found that breast cancer incidence was reduced by 50% in tamoxifen-treated women
compared to placebo treated controls [30]. In 1999, the Food and Drug Administration
approved tamoxifen for the reduction of breast cancer risk, and later, it was the first drug
approved for the prevention of any cancer. The reinvention of tamoxifen from a failed
“morning after pill” to the first targeted therapy for breast cancer and first
chemopreventive provided the clinical research community with an invaluable new
therapeutic tool to pioneer the strategy of long term anti-hormonal therapy and
chemoprevention [31].
2.2. Mechanism of Action
The mechanisms of tissue selective, mixed agonist-antagonist action of tamoxifen
and other SERMs are still being determined, but the unique actions may be explained by
interactive mechanisms. The fundamental elements that factor into the tissue-selective
actions are the differential estrogen-receptor expression in a given target tissue, the
differential ER conformation on ligand binding, the precise sequence compositions of the
EREs, and the differential expression and binding of co-regulator proteins to the estrogen
receptor [24]. Because of their distinct biological activities the relative expression of ER
and ER in different tissues will affect the response to both estrogens and tamoxifen.
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As explained in 1.2.1, ER and ER have distinct biological activities and ER
can in fact suppress the actions of ER by forming a heterodimer with it. Thus, the
relative levels of expression of these two receptor isoforms will affect the cellular
responsiveness to estrogens. Tamoxifen binds to both isoforms and affects the cellular
responsiveness of each [32]. SERMs function as pure antagonists at ER on genes
containing estrogen response elements but function as partial agonists when acting via
ER [16].
Recently, it has been demonstrated via protein crystallography and surface
probing techniques that binding of tamoxifen to ER results in a unique conformational
change. When estrogen binds to the hydrophobic pocket of ER, the pocket is closed by
helix 12 of the protein resulting in the activation of AF-2, but when tamoxifen binds to
the pocket, it prevents reorientation of helix 12 [33]. The precise composition of the
ERE’s can also alter the structural conformation of the receptor.
Many co-regulator proteins bind to ER and modulate ER function. As ER
regulates the rate of gene transcription through its association with co-regulators, the
overall balance of expression levels of co-activators and co-repressors have been shown
to be an important determinant of the tissue-specificity of SERMs (Figure 2-1). For
example, tamoxifen recruits a co-activator complex to ER genes in endometrial cells
where it acts as an agonist, but a co-repressor complex to the same gene in the breast
where it acts as an antagonist [34]. Figure 2-1 is a schematic representing the role of coregulators in modulating receptor conformation and activity. When tamoxifen binds the
receptor, the receptor adopts an intermediate partial conformation that is neither fully
active nor fully inactive. In the intermediate conformation, the receptor is also subject to
interactions with the relative intracellular concentrations of preferred co-activators or corepressors for its activity [32]. Depending on the unique receptor conformation induced
by ligand binding, varying combinations of co-regulator proteins interact with the
estrogen receptor and modulate its function in a variety of ways [24].
2.3. Treatment of Breast Cancer
Tamoxifen acts as an estrogen antagonist for the breast, and the tissue selective
actions made it the gold standard treatment for ER-positive breast cancer. By acting as a
weak ER agonist in the bone, tamoxifen reduces bone loss. Treatment also induces a
beneficial serum lipid profile by decreasing LDL levels. However, tamoxifen therapy is
also associated with an increase in the risk of endometrial cancer because of its actions as
a partial agonist in the endometrium. Nevertheless, there have been numerous studies
demonstrating efficacy for the treatment and prevention of ER-positive breast cancer.
Tamoxifen is mainly cytostatic and acts by slowing the proliferation of breast cancer cells
by inhibiting their progression from the G1 phase of the cell cycle, but it has also been
shown to induce apoptosis in vitro in breast cancer cell lines and therefore may possess
cytocidal properties in vivo as well [24].
Adjuvant tamoxifen therapy has been demonstrated to significantly reduce the
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Figure 2-1. The potential actions of co-regulators at the ER. The schematic
demonstrates the potential contributions of co-activators and co-repressors to the tissuespecific activities of a SERM.
Reprinted with permission. Jordan, V.C. and B.W. O'Malley, Selective estrogen-receptor
modulators and antihormonal resistance in breast cancer. J Clin Oncol, 2007. 25(36): p.
5815-24 [32].
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risk of recurrence and death from breast cancer. A review of 55 clinical trials of adjuvant
therapy with 37,000 women with breast cancer examined tamoxifen versus no tamoxifen
before recurrence. The proportional reduction in recurrence was 47% after 5 years of
treatment with tamoxifen and the proportional reduction in mortality was 26% after 10
years [35]. The absolute improvements in 10-year survival were 10.9% in lymph nodepositive and 5.6% in lymph node-negative breast cancer, and women with ER–negative
cancer had very limited benefit [24]. As discussed in Chapter 2.1, the widening use of
long-term tamoxifen treatment led to its inclusion in randomized primary-prevention
trials, and the NSABP trial demonstrated a 50% reduction in the risk of breast cancer in
high risk patients when compared to placebo treated controls [30].
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CHAPTER 3. MECHANISMS OF RESISTANCE
Despite the relative safety and significant anti-neoplastic and chemopreventive
activities of tamoxifen, most initially responsive breast tumors develop resistance [33].
The development of resistant tumors remains a major obstacle in the struggle to treat and
prevent breast cancer. Approximately 30% of ER-positive breast cancers do not respond
to tamoxifen treatment (de novo resistance), and of the tumors that initially respond to
treatment, the majority develops resistance over time (acquired resistance), despite the
continued expression of ER. Studies have shown that ER continues to regulate tumor
development in most resistant cases and the majority are still responsive to fulvestrant
and AIs, indicating that estrogen remains an important regulator of tumor growth [11].
Drug resistance to anti-hormonal therapy in breast cancer was originally viewed as the
ER-negative cells overgrowing ER-positive cells whose growth had been arrested from
tamoxifen treatment; however, this view is no longer accepted. It is unlikely that one
single mechanism can explain hormonal resistance in all breast cancer patients, but recent
work has provided details about the types of resistance and the mechanisms by which
they may develop.
Three classes of resistance are acknowledged: metabolic resistance, intrinsic (or
de novo) resistance, and acquired resistance [32]. Tamoxifen is a prodrug that is
metabolically activated. Generated via CYP3A4/5 and CYP2D6 (Figure 3-1), 4hydroxytamoxifen and especially endoxifen are important active metabolites of
tamoxifen that are necessary to achieve the maximal anti-estrogenic and antitumor effects
of tamoxifen. These metabolites have been shown to posses a 100-fold greater affinity for
ER and 30- to 100- fold greater potency in suppressing ER-dependent proliferation and
gene expression [15]. Wide variations in both of these enzymes responsible for tamoxifen
metabolism exist in the population and the clinical response to tamoxifen therapy is likely
to depend on the cumulative effect of these metabolites [36]. The clinical relevance of
these variants on patient outcomes in the treatment of breast cancer with tamoxifen is
unclear and must be addressed in large populations and with prospective studies [37].
Intrinsic resistance is exemplified by tumors that fail to respond to initial
tamoxifen therapy, while acquired resistance develops over the time course of tamoxifen
therapy. The remainder of this review will focus on these types of resistance. Such
mechanisms include modifications of ER status and alterations in the intracellular
environment via changed expression of co-regulators and the influence of kinase and
growth factor signaling.
Tamoxifen’s effects are mediated via the ER, and therefore the degree of
expression of ER is a strong predictor of response to tamoxifen treatment, and the status
of ER expression is critical [17]. As explained previously, tamoxifen acts as an antagonist
at ER, but may act as an agonist to ER. The loss of expression, mutation or change in
activity of ER, as well as an alteration in the expression of ERβ are potential
mechanisms by which ER status may change, thus affecting tamoxifen’s actions and
resulting in the development of clinical resistance.
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Figure 3-1. The metabolism of tamoxifen. Tamoxifen is metabolized via CYP3A4/5
and CYP2D6 to its active metabolites 4-hydroxytamoxifen and endoxifen.
Reprinted with permission. Jordan, V.C., New insights into the metabolism of tamoxifen
and its role in the treatment and prevention of breast cancer. Steroids, 2007. 72(13): p.
829-42 [37].
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3.1. Estrogen Receptor Status
3.1.1. Loss of ERα Expression
The expression of ER has long been regarded as a strong predictor of clinical
response to tamoxifen and any anti-estrogen therapy. Anti-estrogen therapies are only
effective in cancers that are ER-positive and dependent on ER signaling for growth and
proliferation. Loss of ER may confer resistance to any anti-estrogen therapy, and the
lack of ER expression is the primary mechanism of de novo or intrinsic resistance to
tamoxifen [15]. The large majority of ER-negative breast cancer tumors demonstrate
intrinsic resistance, but a small percentage of ER-negative tumors that are progesterone
receptor (PgR) positive respond to anti-estrogen treatment. PgR is considered another
important indicator of anti-estrogen response because studies show that roughly 70% of
ER-positive/PgR-positive tumors effectively respond to tamoxifen, while only 34% of
ER-positive/PgR-negative tumors respond [11]. “The predictive power of PgR
expression is likely related to the ability of estrogens to induce its expression. Thus, the
presence of both ER and PgR may reflect the existence of an at least partially functional
ER signaling pathway” [38].
Alterations of the ER gene in the form of point mutations, deletions, or
insertions are rare events that do not explain the ER-negative status of 20–30% of breast
cancers and epigenetic mechanisms are now being investigated [39]. Work in cultured
human breast cancer cells previously demonstrated that the absence of ER gene
expression is associated with an increased capacity to methylate DNA, as well as
extensive methylation of CpG islands of the ER gene. These results suggest that
abnormal methylation may account for transcriptional inactivation [40]. Other work
suggests that increased deacetylation of histones via HDAC may result in the loss of ER
expression.
It was once thought that the loss of ER expression may be responsible for
acquired resistance to tamoxifen, but only a relatively small percentage of tumors with
acquired resistance do not express ER [41]. Many tamoxifen resistant patients will still
respond to second line anti-estrogen treatment with fulvestrant or an aromatase inhibitor
indicating a continued role of estrogen and the ER in the progression of the cancer.
3.1.2. Mutations to ERα
Several studies have demonstrated that mutations of ER can confer resistance to
tamoxifen. A naturally occurring mutation of ER has been identified that results in
increased estrogen sensitivity and increased proliferation at lower estrogen concentrations
[42]. However, it has been reported that only 1% of the primary breast cancers have point
mutations in the ER gene [43]. Therefore such mutations of ER are unlikely to contribute
significantly to the development of resistance to tamoxifen. These types of point
mutations as well as deletions, duplications, insertions and alternative splicing events
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have the potential to regulate ER function and therefore should be considered, but
resistance commonly develops in their absence.
3.1.3. Altered Expression of ERβ
The data regarding the expression level of ER and tamoxifen resistance is
conflicting. As discussed previously, ER has the ability to repress the activity of ERα
[44]. Studies have reported low levels of ER to be predictive of tamoxifen resistance,
while others have shown high levels of ER in resistant breast cancer cells [15]. Like
ERα, ER expression in breast cancer is associated with a better prognosis. However, the
contrasting results of studies make a conclusion regarding the role of ER in tamoxifen
resistance unfeasible at this point in time, and more work is necessary to establish
whether ER expression is important in tamoxifen resistance.
3.1.4. ER Phosphorylation
ER is a target of serine, threonine and tyrosine phosphorylation, and ER
phosphorylation is a key element of non-genomic actions in response to estrogen, but has
also been shown to affect genomic transcription mediated events [11]. Introduction of
mutations at these sties of phosphorylation often results in enhancement of ER
transcriptional activity. The kinases that mediate these phosphorylations include Src,
PAK1, PKA, cyclin A, AKT and ERK1/2. Many of the potential mechanisms discussed
below alter the phosphorylation and thereby the activity of ER possibly contributing to
the resistant phenotype.
3.2. Co-regulator Expression
Co-regulators play an important role in mediating the transcriptional activity of
ER. Because many of these may be present at rate-limiting levels in the nucleus, changes
in their level of expression and/or activity can lead to alterations of ER signaling [15]. In
particular, over expression of co-activators and down regulation of co-repressors may
contribute to tamoxifen resistance. “An imbalance in the expression of co-activator and
co-repressor genes may impair tamoxifen activity either by abolishing the anti-estrogenic
effect or by switching the effect from anti-estrogenic to estrogenic,” but few studies have
been studied the role of co-regulators in tamoxifen resistance [45].
3.2.1. Co-activators
In vitro studies have demonstrated that increased co-activator expression can
enhance the agonist activity of tamoxifen. AIB1(also called SRC-3, RAC3, ACTR, and
p/CIP) is an ER co-activator thought to be important in breast cancer. AIB1 is
phosphorylated and activated by mitogen-activated protein kinases (MAPKs), and high
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levels of activated AIB1 may potentially reduce the antagonist effects of tamoxifen,
especially in tumors that also over-express the HER-2 receptor, a member of the
epidermal growth factor (EGF) receptor family that activates MAPKs [46]. A1B1 is overexpressed in over 50% of breast tumors [47], and enhances the agonist effect of
tamoxifen in vitro [48].
A retrospective study investigated the hypothesis that tumors with a relatively
high abundance of AIB1 are less responsive to tamoxifen therapy in 187 patients having
received adjuvant tamoxifen and 119 patients with no adjuvant treatment. High AIB1
expression in patients not receiving adjuvant tamoxifen therapy was associated with
better prognosis and longer disease free survival. In contrast, for patients who did receive
tamoxifen therapy, high AIB1 expression was associated with worse disease free
survival, which may be indicative of tamoxifen resistance [46]. Patients with tumors
expressing high levels of both AIB1 and HER-2 had worse outcomes with tamoxifen
therapy than all other patients combined suggesting a cross-talk between ER and growth
factor signaling pathways (discussed in Section 3.3.). This work supports the hypothesis
that increased expression or activation of ER co-activators could enhance the agonist
activity of tamoxifen and potentially contribute to resistance.
3.2.2. Co-repressors
The co-repressor NCoR has been shown to interact with ER when bound to 4OHtamoxifen and acts as part of larger protein complex with histone deacetylase activity that
promotes chromatin condensation and leads to target-gene silencing [45]. NCoR binds
avidly to ER in the presence of tamoxifen, but when NCoR activity is blocked with an
antibody in MCF-7 human breast cancer cells, tamoxifen instead acts as an agonist [49].
MCF7 cells were also implanted into ovarectomized, athymic nude mice and the animals
were subsequently treated with tamoxifen. NCoR levels declined in many of the tumors
that acquired resistance to tamoxifen, relative to tumors with continued response. This
data demonstrates that a decrease in expression of NCoR can result in a change in
tamoxifen activity and potentially contribute to resistance.
Girault et al. analyzed the mRNA expression (RT-qPCR) of NCoR in a welldefined series of ER-positive breast cancer patients who exclusively received adjuvant
tamoxifen therapy after surgery. They demonstrated that low expression of NCoR is
associated with significantly shorter relapse-free survival in tamoxifen treated patients
[50]. Both this work in vivo and the work in vitro demonstrate a mechanism by which
down regulation or decreased activity of the co-repressor NCoR can contribute to the
development of resistance to tamoxifen.
3.3. Growth Factor Signaling Pathways
ER signaling does not exist in isolation within the intracellular environment, and
many other elements, most notably those comprising growth factor transduction cascades,
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can influence or be influenced by ER signaling [51]. As previously described, in addition
to the genomic actions, ER may initiate rapid cellular signaling via direct interaction with
components of growth factor signaling pathways. Activation of ER via the non-genomic
pathway outside the nucleus results in phosphorylation, and activation of surface tyrosine
kinase receptors (such IGF-IR, EGFR, and HER2) and also with cellular kinases and
adaptor molecules (such as c-Src and PI3K) [10]. Many of these interactions lead to the
activation of key downstream signaling kinases such as MAPK and AKT, which also
have the potential to phosphorylate and thereby activate ER itself or its co-activator
proteins (Figure 3-2) [10].
Alterations in these signaling cascades have the ability to alter the therapeutic
responses to anti-estrogenic drugs such as tamoxifen and potentially lead to the
development of resistance. The inappropriate activation of growth factor signaling
cascades can potentially occur through an enhanced supply of growth factor ligands, via
up-regulation or through increased activation of the receptors or their downstream
signaling cascades [52]. Such changes can potentially stimulate growth and proliferation
of breast cancer cells independently of ER or via cross-talk with ER, and thereby
contribute to resistance.
3.3.1. EGFR and HER2
Epidermal growth factor receptor (EGFR) and Human epidermal growth factor
receptor 2 (HER2) are transmembrane receptor tyrosine kinases that signal via MAPK,
ERK1/2, PI3K, and AKT to stimulate proliferation, differentiation, and cell survival.
Dysregulation and over-expression of EGFR can lead to transformation of cells in vitro
and tumor formation in nude mice [53]. “Increased EGFR, its cognate growth factor
ligands (EGF, TGF-, amphiregulin), or hyper-activation of its signaling elements have
invariably been associated with anti-hormonal resistance, aggressive clinicopathology,
disease metastasis, and poor prognosis” [54]. In vitro transfection studies indicate a
causal role of EGF receptor expression in breast cancer progression to hormone
independence [55]. Other investigators have demonstrated that acquisition of resistance
in ER-positive breast cancer cell lines following long term treatment with tamoxifen
often coincides with over-expression of EGFR and activation of downstream molecules
[11].
ER is a regulator of the cell-cycle, and estrogen-activated ER results in a negative
feedback to control cell growth by down-regulating genes involved in proliferation, such
as EGFR and HER2 [15]. In the presence of estrogen, ER-positive breast cancer cells
suppress EGFR expression, but tamoxifen, by antagonizing ER, may result in increased
expression and activation of these signaling pathways. EGFR activates MAPK and AKT
to stimulate proliferation and cell survival, and these signaling kinases may also
phosphorylate and thereby activate ER or its co-activator proteins resulting in increased
expression of ER genes [10]. Two ER regulated genes of note are the EGFR ligands
amphiregulin and TGF. Through this mechanism, tamoxifen may enhance the
transcription of these ligands creating an autocrine loop that maintains cell growth and
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Figure 3-2. ER crosstalk with growth factor receptor pathways. This signaling
diagram illustrates the potential crosstalk between ER and many of the growth factor
pathways discussed that potentially contribute to tamoxifen resistance in breast cancer.
Reprinted with permission. Massarweh, S. and R. Schiff, Unraveling the mechanisms of
endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res,
2007. 13(7): p. 1950-4 [10].
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proliferation despite tamoxifen treatment [56]. An example of an autocrine signaling loop
resulting in cell growth despite anti-hormone treatment is depicted in Figure 3-3.
There is substantial evidence supporting the up-regulation of EGFR as a
mechanism for the enhanced cross talk with ER; however, another group has
demonstrated another potential mechanism to enhance the interaction between EGFR and
ER [57]. Fan et al. demonstrated that long-term exposure of hormone-sensitive MCF-7
breast cancer cells to tamoxifen causes cytoplasmic translocation of ER. They report
that the elevation in the levels of extra-nuclear ER increases the opportunity of ER to
associate with factors that facilitate activation of the MAPK pathway. The enhanced
interaction between ER and EGFR is associated with an increased ability of EGF,
estrogen and tamoxifen to stimulate MAPK, and tamoxifen elicited rapid phosphorylation
of MAPK in resistant cells in contrast to its antagonistic activity in control cells [57].
Their results further support that enhanced non-genomic function of ER via cooperation
with the EGFR pathway represents a mechanism responsible for acquired tamoxifen
resistance.
HER2 has also been implicated in de novo resistance to tamoxifen. Breast cancer
patients whose ER-positive tumors express high levels of the co-activator AIB1 and
HER2 treated with tamoxifen experience substantially more recurrences than those with
ER-positive tumors that have lower expression of one or both proteins [46]. Tamoxifen
acts as an antagonist in parental MCF-7 cells, which express high AIB1 but low HER2
expression, and tamoxifen behaves as an agonist in MCF-7 cells expressing high levels of
both HER2 and AIB1 [58]. This agonist activity on gene expression and cell proliferation
resulted in tumor growth stimulation by tamoxifen demonstrating de novo resistance. In
this intracellular environment, tamoxifen-bound ER recruits the co-activator rather than
co-repressors, resulting in agonist activity [15]. Both the clinical and in vitro data indicate
that both HER2 and AIB1 are necessary for this resistant phenotype. This mechanism of
resistance is also a function of enhanced cross-talk as the enhanced signaling of HER2
results in the phosphorylation and activation of both ER and the co-activator AIB1. The
agonist effect of tamoxifen in the resistant cells is reversed by administration of gefitnib,
a tyrosine kinase inhibitor [58]. Gefitnib restores the recruitment of co-repressor
complexes by tamoxifen-bound ER resulting in a return of the antagonistic effects.
3.3.2. IGF-1R
The role of IGF signaling in tamoxifen resistance is much less clear than that of
EGFR and HER2, but evidence for a role of IGF-1R is emerging [11]. IGF-1R is also a
member of the receptor tyrosine kinase family, and it is activated after ligand binding of
insulin, IGF-I, or IGF-II resulting in the activation of downstream signaling pathways
including AKT, MAPK and PI3K cascades [58]. As previously discussed these
signaling pathways have been shown to influence cell survival and proliferation. IGF-IR
is an ER-dependent gene and tamoxifen, which effectively inhibits classically ERdependent transcription, can effectively reduce its expression [59]. The data regarding the
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Figure 3-3. Autocrine signaling loop counteracting the anti-proliferative effect of
endocrine therapy. Anti-estrogen treatment may result in an increase of EGFR/HER2
expression. These receptor tyrosine kinases activate the downstream MAPK/AKT
signaling cascade, which phosphorylate and activate nuclear ER in the absence of ligand.
Persistent ER activation leads to increased transcription of ER-sensitive genes, including
amphiregulin and TGF, which also activate EGFR completing the autocrine proliferative
loop. The net effect is a reduction or elimination of the anti-proliferative effect of
endocrine therapy.
Reprinted with permission. Zilli, M., et al., Molecular mechanisms of endocrine
resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta,
2009. 1795(1): p. 62-81 [15].
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levels of IGF-1R in tamoxifen-resistant breast cancer lines is mixed, however there is
increasing evidence supporting synergistic interactions between IGF-1R, ER and EGFR.
Estrogens result in an increase in expression of the IGF-IR and growth, while IGFs prime
the activation of several kinases that are able to phosphorylate ER and initiate estrogenmediated gene expression [58].
One mechanism by which IGF-1-treated breast cancer cells may escape
tamoxifen-induced apoptosis is via the IGF-mediated activation of AKT and subsequent
phosphorylation of ER leading to the ligand-independent activation of ER [60]. Recent in
vitro studies have aimed at elucidating the role of IGF-1R in breast cancer resistance.
Unlike EGFR, several studies have reported that tamoxifen continues to suppress IGF-1R
level even during the development of resistance. However, Massarweh et al. discovered
that p-IGF-IR, although initially reduced in the tamoxifen-sensitive tumors, is increased
at the time of resistance, suggesting that IGF-IR becomes activated at the time of
acquired resistance and then augments important cell survival pathways [59]. It has also
been shown that inhibition of IGF-1R (by an anti-IGF-1R antibody [61] or by an IGF-1R
tyrosine kinase inhibitor [58]) reduces growth of tamoxifen-resistant MCF-7 breast
cancer cells. An in vivo model also demonstrated that an IGF-1R monoclonal antibody
enhances the anti-tumor activity of tamoxifen in estrogen receptor positive breast cancer
xenografts [62].
Data also suggest that bi-directional crosstalk pathways between the epidermal
growth factor family of receptors (erbB) and IGF-1R exists, and this interaction has been
suggested to in part mediate the development of acquired resistance. In vitro work has
shown that increased IGF-IR signaling interferes with the action of the HER-2 antibody
trastuzumab in HER2 positive breast cancer cells [63]. Similarly, these breast cancer cells
displayed enhanced cytotoxic effects when cultured with trastuzumab and an anti-IGF1
receptor antibody in combination [64]. Both activated EGFR and HER2 are also
sufficient for conferring resistance to an IGF-1R inhibitor [65]. These data suggest that
alterations to both the IGF-1R and erbB receptor pathways may occur in a reciprocating
fashion leading to resistance [66]. The mechanism by which IGF may interact with EGFR
and ER in breast cancer cells is becoming clearer; however, to date no conclusive clinical
data has been reported regarding the clinical significance of IGF-IR’s role in tamoxifen
resistance.
3.3.3. Cas, c-Src and BCAR
Several cytoplasmic proteins whose functions are also coupled to growth factor
receptors have been connected to tamoxifen resistance. In particular, BCAR and Cas are
two implicated proteins that were discovered in a screening to identify proteins capable
of inducing anti-estrogen resistance in vitro [11]. It has since been noted that patients
with primary breast tumors expressing high levels of Cas protein are associated with
more rapid disease recurrence and have a greater risk of (intrinsic) resistance to
tamoxifen [67].
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3.3.3.1 Cas and c-Src
High expression of Cas (p130Cas) is associated with resistance to tamoxifen in
both tissue culture and in human tumors. Cas is a scaffold protein that assists in the
formation of multi-protein complexes, by promoting protein-protein interactions [68]. It
is an important aspect of signal transduction pathways that modulate cell motility,
survival and proliferation. Riggins et al. demonstrated that Cas binds to and activates cSrc, a protein tyrosine kinase and results in phosphorylation of c-Src substrates, such as
EGFR and signal transducer and activator of transcription (STAT) 5b. Inhibition EGFR
and STAT5b abrogates the effect of Cas overexpression, supporting the significance of
these c-Src substrates in the development of resistance [69]. Pharmacologic inhibition of
c-Src in MCF-7 cells also enhances the inhibitory effects of tamoxifen on cell growth
[70]. It is clear that Cas overexpression diminishes the anti-proliferative and proapoptotic effects of tamoxifen on breast cancer cells in vitro, and data suggests it
accomplishes this via the activation of the Cas/c-Src/EGFR/STAT5 signaling pathway.
Whether these pathways are also clinically significant in resistance to tamoxifen
has not yet been established; however, a large percentage of human breast tumors express
high levels of both c-Src and Cas, as well as elevated c-Src kinase activity, and “cSrc/Cas complexes can be isolated from a majority of breast cancer cell lines” [11].
These data together suggest that tamoxifen resistance may be mediated in part through
this mechanism involving c-Src and Cas.
3.3.3.2 BCAR3
Breast cancer anti-estrogen resistance 3 (BCAR3) was discovered in a genetic
screening for genes associated with anti-estrogen resistance. It encodes a component of
intracellular signal transduction and interacts directly with Cas. Transfer of the BCAR3
gene by cell fusion or transfection to breast cancer cells induces anti-estrogen resistance
suggesting that up-regulation of BCAR3 (also knowns as AND-34) stimulates an
alternative growth path independent of hormone, both in the presence and absence of
anti-estrogens [71]. BCAR3 has since been shown to alter the activity, expression, and
intracellular location of many proteins, including Cas, Ras and Rho family GTPases, and
Pak1 [11]. Work by Felekkis et al. showed BCAR3 over-expression induced antiestrogen resistance in human breast cancer cell lines by activating PI3K, which induced
Rac activation and finally resulted in anti-estrogen resistance [72]. While the data suggest
that BCAR3 over-expression has the potential to result in resistance in cultured cells, the
role of BCAR3 in the clinical setting of resistance has not yet been established.
3.3.4. PI3K and AKT
Downstream of growth factor receptors and adapter protein activation, signaling
intermediates such as AKT play an important role in cell proliferation, survival, and
endocrine resistance [11]. Receptor tyrosine kinases, such as the growth factor receptors
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EGFR and IGF-1R, activate PI3K, which in turn activates AKT, leading to substrate
phosphorylation. The tumor suppressor PTEN antagonizes AKT and acts as a counter
balance acting as a phosphatase. AKT activation promotes cell survival by inhibiting
apoptosis and also plays a roll in regulation of the cell cycle. Over-expression of
constitutively active AKT in MCF-7 breast cancer cell lines results in estrogen
independence and resistance to tamoxifen [73], and activation of AKT is increased in
tamoxifen-resistant MCF-7 breast cancer cells [74]. The exact mechanisms by which
AKT may confer anti-estrogen resistance are unclear.
Phosphorylation of ER by AKT is one proposed mechanism demonstrated in vitro
to result in decreased sensitivity to tamoxifen. Phosphorylation of Ser-167 by AKT
results in increased ER binding to DNA and increased recruitment of the co-activator
SRC3 potentially resulting in increased agonism [75]. In ER-positive breast cancer cell
lines, PI3K-mediated AKT phosphorylation of ER results in receptor activation in the
absence of estrogen [60]. AKT has also been shown to enhance co-activator recruitment
to ER and to potentiate ER transcriptional activity [60]. Evidence from in vitro studies
supports a role of AKT-mediated phosphorylation of ER, but the clinical significance in
tamoxifen resistance remains unclear.
AKT can also indirectly activate mTOR which also controls cell growth, survival,
and apoptosis [76]. In response to activation by growth factor receptors, AKT
phosphorylates and inactivates the tuberous sclerosis complex, which acts as a negative
regulator of mTOR. Blockage of the PI3K/AKT signaling pathway by pharmacologic
mTOR inhibition successfully restores the effectiveness of tamoxifen in MCF-7 breast
cancer cells with constitutively active AKT [77]. While a definitive role of mTOR in
resistance has not been determined, mTOR is considered an attractive therapeutic target
for treating breast cancer [11].
3.3.5. Stress-Activated Protein Kinase/c-Jun Kinase Pathway
Jun NH2-terminal kinases (JNKs) and stress activated protein kinases (SAPKs),
which are activated by cellular stresses, increase AP-1 transcriptional activity via
phosphorylation. AP-1 is a transcription factor heterodimer composed of Jun and Fos
family members, which binds to DNA at AP-1 response elements [78]. In vitro work has
demonstrated that the development of tamoxifen resistance is accompanied by increased
AP-1 DNA binding [79]. Johnston et al. examined a panel of 30 ER-positive primary
human breast tumors with acquired tamoxifen resistance, and these tumors also displayed
a significant increase in AP-1 DNA binding activity when compared to untreated control
tumors [80]. In a tamoxifen-resistant xenograft model, increased phosphorylated c-Jun
and JNK levels accompanied the increase in AP-1 dependent transcription following
tamoxifen treatment, and the conversion to a resistant phenotype was associated with an
increase in oxidative stress [81]. It is known that tamoxifen can induce intracellular
oxidative stress, and this data supports the model in which tamoxifen-induced oxidative
stress leads to activation of JNK and SAPK resulting in increased AP-1 activity and could
contribute to resistance [17].
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3.4. Cell Cycle Regulators
Cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors are the major
regulators of cell cycle progression [11]. Estrogen accelerates the progression from G1 to
S phase, while tamoxifen inhibits cell cycle progression by affecting these key cell cycle
proteins [82]. These expression and activity of these proteins have been demonstrated to
have the potential to significantly impact tamoxifen sensitivity and resistance.
3.4.1. Cyclin D1
Essential for early progression through the G1 phase, cyclin D1 both modulates
CDK4/6-dependent phosphorylation of the tumor suppressor Rb and sequesters the CDK
inhibitors p21 and p27 [11]. Cyclin D1 is a direct transcriptional target of estrogen
signaling, and therefore tamoxifen reduces cyclin D1 expression [83]. In vitro sustained
expression of cyclin D1 is evident in breast cancer cells during their acquisition of
tamoxifen resistance [84], and down-regulation of cyclin D1 with siRNA restored the
sensitivity of these cells to tamoxifen [85]. Cyclin D1can potentiate the transcriptional
activity of the ER independently of estrogen and may not be inhibited by tamoxifen [86].
Clinical studies also support the role of cyclin D1 in tamoxifen resistance. Patients with
cyclin D1 negative tumors show better relapse free survival on tamoxifen, and cyclin D1
expression is correlated with a poorer outcome of tamoxifen treatment [87]. Multiple
clinical studies have demonstrated that breast cancer patients also show that cyclin D1
over-expression correlates with poor outcome on tamoxifen treatment [88, 89].
3.4.2. Cyclin E
Cyclin D1 inhibits Rb early in G1 phase, and the transcription factor E2F strongly
induces the expression of cyclin E, which associates with CDK2 to form an active
complex that promotes entry into S phase [90]. Cyclin E and CDK2 activity is
antagonized by the CDK inhibitors p21 and p27. The contribution of cyclin E to
tamoxifen resistance is unclear, but over-expression of cyclin E in MCF-7 cells partially
counteracts the growth arrest mediated by tamoxifen [91]. More studies are necessary to
determine the mechanisms by which cyclin E is induced in breast cancer and its role in
the induction of resistance.

3.4.3. p21 and p27
p21 and p27 are CDK inhibitors and are negative regulators of cell cycle
progression. These proteins counteract the activities of cyclin D1 and cyclin E. In MCF7 cells, tamoxifen increase the expression of p21 and p27 during cell cycle arrest, but
down-regulation of these by antisense inhibition prevents the growth inhibitory effects
[92]. p27 induction in breast cancer cells by tamoxifen induces quiescence and
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insensitivity to growth stimulation by growth factors such as IGF-I and EGF [93].
Somatic deletion of the p21 gene in human breast cancer cells resulted in
hyperphosphorylation of ER causing an increased gene expression of ER regulated
genes [94]. These studies demonstrate that p27 and p21 are critical for the inhibitory
effects of tamoxifen in inhibiting breast cancer cell growth.
c-Myc, a transcription factor whose expression is frequently altered in human
breast cancer, also plays a role in regulating the activity of p21. Increased c-Myc
expression can rescue the growth arrest mediated by anti-estrogen treatment by activating
CDK2/Cyclin E complex [95]. In vitro over-expression of c-Myc reduces the expression
of p21 in response to tamoxifen potentially mediating tamoxifen resistance [96]. They
also demonstrate that p21 expression in anti-estrogen resistant cells is increased when
treated with c-Myc siRNAs.
Clinical data also supports a role of these CDK inhibitors in response to
tamoxifen treatment. In premenopausal women with early breast cancer, an increase in
p27/KIP1 expression was able to predict better relapse free survival upon tamoxifen
combination treatment [97]. A multivariate analysis of their data revealed decreased p27
expression to be correlated with poor outcome upon combination endocrine therapy.
Localization of these CDK inhibitors has also been implicated in the development of
resistance. Perex-Tenorio et al. showed that increased activity of the PI3K and MAPK
pathway promotes p21 localization into cytoplasm through phosphorylation of residues
within their nuclear localization sequences [98]. The significance of their in vitro data is
supported by immunohistochemistry in frozen human tumors. They demonstrated that
increased cytoplasmic localization of p21 is correlated with a poorer response to
tamoxifen treatment in a cohort of 280 women.
3.5. c-ABL
c-ABL is a non–receptor tyrosine kinase with multiple functions in the regulation
of cell migration, responses to oxidative stress and DNA damage, cell proliferation, and
survival [99]. The oncogenic potential of c-ABL was first discovered in leukemias, but
has recently been found it is not confined to hematopoietic malignancies [100]. Studies
now indicate that c-ABL has a potential role in breast carcinogenesis. Zhao et al.
demonstrated that c-ABL interacts with ER resulting in enhanced ER activity and
together promote resistance to tamoxifen [100]. They report that c-ABL is required for
maintaining ER transcriptional activity and that silencing c-ABL results in the
sensitization of ER-positive breast cancer cells to tamoxifen treatment. They report that
the expression of c-ABL is a frequent event in primary breast cancer tumor tissues, and
the expression of c-ABL in ER-positive tumors is significantly correlated with disease
progression and metastasis. This work suggests c-ABL as a potential therapeutic target
and prognostic tumor marker for breast cancer.
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CHAPTER 4. CONCLUSION
Endocrine treatment of ER-positive breast cancer with tamoxifen, and later on
with aromatase inhibitors and fulvestrant, was the first target-based therapeutic strategy
in oncology [101]. Unfortunately, a substantial proportion of patients, despite being ER
and/or PR positive, are either primarily resistant or will develop resistance during the
course of their disease. Delineation of the molecular mechanisms underlying the
development of resistance will allow development of treatment strategies to enhance
response and compromise resistance.
It has become apparent that ER transcriptional actions are not just determined by
the ligand, but also by complex interactions between co-regulatory molecules and
multiple signaling pathways, which provide several potential mechanisms by which
cancer cells may become estrogen-independent and tamoxifen-resistant [17].
Experimental models have demonstrated that the development of resistance is
accompanied by the many mechanisms discussed. Clinical data further support several of
these mechanisms. Further elucidation of the clinically relevant pathways of resistance,
biomarkers reflecting the activity of these pathways and surrogate biomarkers predictive
of response are therefore critical to determine which therapeutic strategies should be
tested [102]. Some pharmacological agents targeting these pathways are currently
clinically available and others are in development, but it is imperative to remember that
there are likely to be several clinically significant pathways to resistance and that some
will be important in certain patients but irrelevant in others. Gene expression analysis and
molecular profiling have increased our understanding of the mechanisms of response and
resistance, and these approaches are currently being used to develop gene signatures that
may predict clinical responses to treatment [11].
Resistance to SERMs, aromatase inhibitors, and SERDs are likely to be mediated
by distinct pathways, which explains the lack of cross-resistance between the different
classes of drugs [15]. Therefore, the sequential use of endocrine agents is the supported
treatment plan, but the currently available clinical, experimental, and pharmacokinetic
data do not support the concomitant use of hormonal agents [15]. However,
combinatorial therapies of tamoxifen (or other hormonal agents) with drugs aimed at the
signaling pathways underlying the development of resistance may be a potential means of
delaying the onset of resistance. A number of clinical trials have sought to determine
whether the addition of signal transduction inhibitors to endocrine therapy may overcome
endocrine resistance or delay its development [102]. Trials using HER2/neu antagonists,
tyrosine kinase inhibitors, multikinase inhibitors, src inhibitors, and mTOR antagonists
are currently underway in the treatment of breast cancer. Despite an improved
understanding, resistance to all forms of endocrine therapy remains a significant clinical
problem. A clearer understanding of the clinically significant mechanisms by which
resistance develops is critical for improving the treatment of patients with breast cancer
as well as in the development of new drugs and optimal treatment strategies.
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